United Community Banks, Inc. (UCB) Covered Calls

UCB S.A. is a global biopharmaceutical company based in Belgium, specializing in neurology and immunology. It develops innovative medicines for severe diseases, including epilepsy, osteoporosis, and psoriasis. UCB focuses on transforming the lives of people living with severe conditions through science-led solutions.

You can sell covered calls on United Community Banks, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for UCB (prices last updated Tue 4:16 PM ET):

United Community Banks, Inc. (UCB) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
33.10 -0.21 13.31 36.80 568K 13 4.0
Covered Calls For United Community Banks, Inc. (UCB)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 35 0.00 36.80 -4.9% -71.5%
Apr 17 35 0.00 36.80 -4.9% -33.7%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

UCB S.A., headquartered in Brussels, Belgium, is a world-renowned biopharmaceutical company that focuses on the discovery and development of innovative medicines. The company’s core focus areas are neurology and immunology, where it addresses some of the most challenging medical conditions, such as intractable epilepsy and rare autoimmune disorders. UCB operates globally, leveraging a combination of internal R&D and strategic collaborations. By focusing on high-value, niche therapeutic areas, UCB aims to provide transformative solutions that significantly improve the quality of life for patients worldwide while maintaining a sustainable growth trajectory.

Core Business and Products

  1. Neurology Portfolio: UCB is a leader in epilepsy treatment, with blockbuster drugs like Keppra and Vimpat. Its newer generation products, such as Briviact and Fintepla, are designed to treat rare and difficult-to-control forms of epilepsy, providing clinicians with more targeted and effective treatment options.
  2. Immunology Segment: The company’s immunology division is anchored by Cimzia, a TNF-blocker used for various inflammatory conditions. Newer entries like Bimzelx (bimekizumab) represent a breakthrough in treating plaque psoriasis by dual-inhibiting IL-17A and IL-17F cytokines.
  3. Bone Health: Through its partnership with Amgen, UCB co-developed Evenity, a first-of-its-kind treatment for osteoporosis in postmenopausal women at high risk for fracture. This product has become a key driver of the company’s specialty medicines revenue.
  4. Rare Disease and Gene Therapy: UCB is expanding its footprint in rare diseases through acquisitions like Zogenix. It is also investing in gene therapy platforms to address the root causes of genetic neurological disorders.

Competitive Landscape

UCB competes with major global pharmaceutical firms in the highly specialized fields of neurology and immunology. In the immunology and psoriasis market, its primary competitors include AbbVie (Skyrizi) and Novartis (Cosentyx). Within the FcRn inhibitor space, UCB’s Rystiggo competes directly with argenx SE and Immunovant, Inc.. For its epilepsy franchise, it faces competition from Jazz Pharmaceuticals and Pfizer. UCB differentiates itself by focusing on "patient-preferred" solutions, such as subcutaneous formulations that allow for at-home administration rather than clinical infusions.

Strategic Outlook and Innovation

UCB’s 2026 strategy is driven by the global "launch phase" of its next-generation portfolio, specifically Bimzelx and Rystiggo. The company is aggressively expanding the label for Bimzelx to include psoriatic arthritis and ankylosing spondylitis, aiming to establish it as a multi-billion-dollar immunology franchise. Management expects double-digit revenue growth through 2027 as these new launches offset the impact of generic competition for its older epilepsy medications. This growth is supported by a robust internal cash flow, which is being reinvested into high-potential mid-stage clinical candidates across the pipeline.

Innovation at UCB is increasingly focused on "digital health" and precision medicine in neurology. The company is developing wearable sensors and AI-driven monitoring tools to help epilepsy patients and doctors track seizure patterns in real-time, allowing for more personalized drug dosing. Furthermore, UCB is advancing several assets in its neuro-inflammation pipeline, targeting the early stages of diseases like Parkinson’s and Alzheimer’s. By combining advanced biological research with digital patient engagement tools, UCB seeks to maintain its leadership in specialized medicine while transitioning toward more data-driven, holistic healthcare solutions.